Stereotaxis, Inc.
Stereotaxis, Inc. (NYSE American: STXS) designs, manufactures and markets robotic systems, interventional devices and information systems for hospitals’ interventional laboratories. Its core technology, Robotic Magnetic Navigation, uses computer-controlled magnetic fields to steer catheter tips, primarily for cardiac… From the company’s description.
Over the twelve months to Jun 30, 2026, Stereotaxis, Inc. reported revenue of $30.07M, down 5.5% from a year earlier, and a net loss of $22.32M. Its operating margin was −75.7%, and operations used $15.29M in cash. In fiscal 2025, it reported revenue of $32.38M, up 20.3% from fiscal 2024, and a net loss of $21.64M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Stereotaxis, Inc. does
In the company’s own words
Stereotaxis, Inc. (NYSE American: STXS) designs, manufactures and markets robotic systems, interventional devices and information systems for hospitals’ interventional laboratories. Its core technology, Robotic Magnetic Navigation, uses computer-controlled magnetic fields to steer catheter tips, primarily for cardiac electrophysiology procedures, including mapping and ablation to treat arrhythmias; the company is also pursuing other endovascular applications. Its products include Genesis and GenesisX robotic systems, Odyssey and Synchrony lab-integration solutions, and devices under the Map-iT, MAGiC and EMAGIN brands, as well as catheter-advancement and related accessories. Customers include hospitals and physicians, supported through direct sales, distributors and service partners; offerings include equipment, procedure-based disposable products, maintenance and software services. Stereotaxis operates as one reportable segment. At year-end 2025, its robotic technology had been used by electrophysiologists at more than 100 hospitals worldwide to treat over 150,000 arrhythmia patients. In 2024, the company acquired Access Point Technologies EP, adding diagnostic catheter design and manufacturing capabilities and the Map-iT product portfolio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- ST.LOUIS, MO
- Fiscal year end
- December
- CIK
- 1289340
- SIC
- 3845
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Stereotaxis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Stereotaxis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Stereotaxis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Stereotaxis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Stereotaxis, Inc.'s last four quarterly filings that the numbers alone won't show?”